Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Remus PharmaceuticalsNSE:REMUS -1.66%56 EV-to-EBITDA is 16.48 as of Aug. 20, 2026, which is 53% below its 10-year median of 35.20. GuruFocus rates NSE:REMUS with a GF Score™ of 56/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 98 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 79.59% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Remus Pharmaceuticals's enterprise value is ₹10,447 Mil.
Remus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹634 Mil. Therefore, Remus Pharmaceuticals's EV-to-EBITDA for today is 16.48.
The historical rank and industry rank for Remus Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NSE:REMUS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.52 Med: 35.2 Max: 235.6
Current: 16.47
During the past 7 years, the highest EV-to-EBITDA of Remus Pharmaceuticals was 235.60. The lowest was 9.52. And the median was 35.20.
NSE:REMUS's EV-to-EBITDA is ranked worse than 79.59% of 98
companies
in the Medical Distribution industry
Industry Median: 8.4
vs NSE:REMUS: 16.47
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Remus Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Remus Pharmaceuticals's share price for today is ₹878.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Remus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹39.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Remus Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, COR, CAH: EV-to-EBITDA Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's EV-to-EBITDA falls into.
Remus Pharmaceuticals's current Enterprise Value is ₹10,447 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Remus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹634 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a EV-to-EBITDA of 16.48 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Remus Pharmaceuticals. This is 53% below median its historical median of 35.20. Over the past decade, Remus Pharmaceuticals' EV-to-EBITDA has ranged from 9.52 to 235.60. According to the industry distribution chart, Remus Pharmaceuticals ranks #78 out of 98 companies in the Medical Distribution industry, placing it in the top 79.6%.
Is Remus Pharmaceuticals' EV-to-EBITDA too high?
Remus Pharmaceuticals' current EV-to-EBITDA of 16.48 is 53% below median its 10-year median of 35.20. Over the past 10 years, this metric has ranged from a low of 9.52 to a high of 235.60. The Medical Distribution industry median EV-to-EBITDA is 8.40. Remus Pharmaceuticals' value of 16.48 is 96.2% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #78 out of 98 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #78 out of 98 companies for EV-to-EBITDA. This places Remus Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 8.40. Remus Pharmaceuticals' value of 16.48 is 96.2% above this benchmark. Historically, Remus Pharmaceuticals' own EV-to-EBITDA has ranged from 9.52 to 235.60 over the past decade. While the company's 10-year median is 35.20 vs. the industry median of 8.40, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.40, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current EV-to-EBITDA of 16.48 is 96.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Remus Pharmaceuticals. For the Medical Distribution industry, the median EV-to-EBITDA is 8.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current EV-to-EBITDA is 16.48, which is 53% below median its own 10-year median of 35.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹878.95 — trading 57.6% below its estimated fair value. The current EV-to-EBITDA is 16.48, which is 53% below median its 10-year median of 35.20 and 96.2% above the Medical Distribution industry median of 8.40. Remus Pharmaceuticals' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current EV-to-EBITDA is 16.48 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹878.95 is trading 57.6% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
EV-to-EBITDA: 16.48 (53% below median its 10-year median of 35.20)
GF Value™: ₹2,071.36 vs. price of ₹878.95 (57.6% below fair value)
Industry Position: 96.2% above the Medical Distribution median (#78 of 98)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
56GF Score
Get the complete analysis for NSE:REMUS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
